HUE050862T2 - Merevedési zavar és más indikációk kezelése - Google Patents

Merevedési zavar és más indikációk kezelése

Info

Publication number
HUE050862T2
HUE050862T2 HUE11852275A HUE11852275A HUE050862T2 HU E050862 T2 HUE050862 T2 HU E050862T2 HU E11852275 A HUE11852275 A HU E11852275A HU E11852275 A HUE11852275 A HU E11852275A HU E050862 T2 HUE050862 T2 HU E050862T2
Authority
HU
Hungary
Prior art keywords
indications
treatment
erectile dysfunction
erectile
dysfunction
Prior art date
Application number
HUE11852275A
Other languages
English (en)
Inventor
Eric Thor Fossel
Original Assignee
Strategic Science & Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strategic Science & Tech Llc filed Critical Strategic Science & Tech Llc
Publication of HUE050862T2 publication Critical patent/HUE050862T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE11852275A 2010-12-29 2011-12-29 Merevedési zavar és más indikációk kezelése HUE050862T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061428213P 2010-12-29 2010-12-29
US201061427999P 2010-12-29 2010-12-29

Publications (1)

Publication Number Publication Date
HUE050862T2 true HUE050862T2 (hu) 2021-01-28

Family

ID=46383543

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11852275A HUE050862T2 (hu) 2010-12-29 2011-12-29 Merevedési zavar és más indikációk kezelése

Country Status (10)

Country Link
US (10) US9463158B2 (hu)
EP (2) EP3721893A1 (hu)
JP (6) JP2014504592A (hu)
CN (3) CN114668851A (hu)
DK (1) DK2658551T3 (hu)
ES (1) ES2811515T3 (hu)
HR (1) HRP20201512T1 (hu)
HU (1) HUE050862T2 (hu)
PT (1) PT2658551T (hu)
WO (1) WO2012092528A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
WO2005102307A2 (en) * 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
AU2009348470B2 (en) 2009-06-24 2015-04-02 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
PT2658551T (pt) 2010-12-29 2020-07-24 Strategic Science & Tech Llc Tratamento da disfunção erétil e outras indicações
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
US20160067252A1 (en) 2013-03-15 2016-03-10 Strategic Science & Technologies, Llc Transdermal delivery of sildenafil and other phosphodiesterase type 5 inhibitors
WO2014152280A1 (en) * 2013-03-15 2014-09-25 Strategic Science & Technologies, Llc Transdermal formulations of fluticasone
US20180078602A1 (en) * 2015-03-04 2018-03-22 K.L.R.M., Llc Methods and compositions for extending the efficacy of phosphodiesterase inhibitors for treating erectile dysfunction, and compositions for inhibiting the onset and slowing the progression of erectile dysfunction
US9949915B2 (en) 2016-06-10 2018-04-24 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
CN107296789A (zh) * 2017-07-08 2017-10-27 天津双硕医药科技有限公司 一种含有枸橼酸西地那非的外用药物组合物
US11452701B2 (en) 2017-12-04 2022-09-27 Johnson & Johnson Consumer Inc. Topical emulsion composition containing nonsteroidal anti-inflammatory drug
WO2021236891A1 (en) * 2020-05-20 2021-11-25 Augusta University Research Institute, Inc. Gut-targeted phosphodiesterase inhibitors

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5940E (fr) 1906-01-30 1906-07-27 Ramier Et Mauberque Soc Radiateur
FR5799M (hu) 1966-03-22 1968-03-25
FR5940M (hu) 1966-10-18 1968-04-08
FR1553063A (hu) 1967-11-28 1969-01-10
US3960782A (en) 1974-09-27 1976-06-01 The Procter & Gamble Company Shampoo compositions which impart high luster and manageability to hair
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
JPS5753404A (en) 1980-09-17 1982-03-30 Kao Corp External preparation for skin obtained by blending plant extract
GB2094142B (en) 1981-03-06 1984-09-26 Lab For Applied Biology Ltd Injectable solution containing theophylline and a basic amino acid
GB2126868B (en) 1982-09-20 1986-03-19 Ralston Purina Co Method of improving the shelf life of processed meat products
DE3327840C1 (de) 1983-08-02 1984-09-20 Blendax Werke Schneider Co Hautpflegemittel
FR2557452B1 (fr) 1983-12-28 1986-08-14 Roussel Uclaf Nouvelles compositions pour les soins de la peau renfermant de l'huile d'onagre et des traits tissulaires de rate
US4681897A (en) 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
JPS60252412A (ja) 1984-05-29 1985-12-13 Nichiban Co Ltd 貼布治療製剤
US4722837A (en) 1984-05-29 1988-02-02 Derma-Cure, Inc. Medicated shampoo composition
US4692462A (en) 1985-03-18 1987-09-08 Menley & James Laboratories, Ltd. Compositions and method of controlling transdermal penetration of topical and systemic agents
US4732892A (en) 1985-07-12 1988-03-22 American Home Products Corporation L-α-amino acids as transdermal penetration enhancers
DE3684564D1 (de) 1985-11-18 1992-04-30 Beecham Group Plc Veterinaere zusammensetzungen.
GB8606368D0 (en) 1986-03-14 1986-04-23 Unilever Plc Skin treatment composition
FR2602678B1 (fr) 1986-08-13 1992-06-05 Drouault Guy Composition pharmaceutique aqueuse a base de sels de magnesium, sodium et potassium pour la regulation des circulations locales
US4940456A (en) 1987-02-10 1990-07-10 Dan Sibalis Electrolytic transdermal delivery of proteins
US4885157A (en) 1987-02-13 1989-12-05 Fiaschetti Mary G Dermal cosmetic composition and applications therefor
DE3715576A1 (de) 1987-05-09 1988-11-24 Wella Ag Neue makromolekulare, oberflaechenaktive, quaternaere n-substituierte chitosanderivate sowie kosmetisches mittel auf der basis dieser neuen chitosanderivate
KR900004875Y1 (ko) 1987-10-02 1990-05-31 삼성전자 주식회사 Pip의 수평 윈도우 신호발생 회로
JPH045231Y2 (hu) 1987-12-16 1992-02-14
US5925372A (en) 1987-12-16 1999-07-20 Novartis Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US4871718A (en) 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
GB2217595B (en) 1988-04-21 1991-11-20 American Cyanamid Co Antiinflammatory gel
DE3827362A1 (de) 1988-08-12 1990-02-15 Basf Ag Pulvrige, hydrophile theophyllinformulierung und verfahren zur ihrer herstellung
WO1990003178A1 (en) 1988-09-30 1990-04-05 Kazuo Watanabe Anti-inflammatory and analgesic compounds, related compositions and methods for preparation and use thereof
KR910700066A (ko) 1989-01-24 1991-03-13 원본미기재 경피약제투여 조성물
US4945901A (en) 1989-03-22 1990-08-07 Burcke Jr Harry J Hand therapy apparatus and method therefor
US5158761A (en) 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5476852A (en) 1989-05-03 1995-12-19 Janssen Pharmaceutica N.V. Method of topically treating acne vulgaris, hyperkeratotic dermatoses, and photo-aging of the skin
US5028435A (en) 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
JP2761939B2 (ja) 1989-09-04 1998-06-04 株式会社コーセー 水中油型乳化化粧料
EP0424028B1 (en) 1989-10-17 1995-09-27 Merck & Co. Inc. S(+)-ibuprofen-L-amino acid and S(+)-ibuprofen-D-amino acid as onset hastened enhanced analgesics
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
EP0441119A3 (en) 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
JPH045231A (ja) 1990-04-20 1992-01-09 Morishita Pharmaceut Co Ltd 慢性痛用鎮痛剤
US5332758A (en) 1990-07-13 1994-07-26 Kanebo, Ltd. Collagen metabolism ameliorant and its use
US5824658A (en) 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
ES2070513T3 (es) 1990-11-14 1995-06-01 Upjohn Co Compuestos de 5-fluoro-2,4,6-pirimidintriamina para prevenir la caida del pelo.
DE4100975A1 (de) 1991-01-15 1992-07-16 Weuffen Wolfgang Kosmetische oder pharmazeutische zubereitungen zur verbesserung der haarqualitaet und foerderung des haarwachstums
US5210099A (en) 1991-02-11 1993-05-11 American Home Products Corporation Analgesic compositions
EP0531495B1 (en) 1991-03-01 1997-08-20 Atherton Investments, Ltd. Therapeutic and cosmetic compositions for treatment of skin
CA2105313A1 (en) 1991-03-01 1992-09-02 Rafael Abad Therapeutic and cosmetic compositions for treatment of skin
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
ATE121390T1 (de) 1991-05-27 1995-05-15 Fujisawa Pharmaceutical Co N-pentadecylnicotinat-n-oxid sowie dieses enthaltendes haarregenerierendes mittel.
JP2636118B2 (ja) 1991-09-10 1997-07-30 三省製薬株式会社 育毛剤
US5254331A (en) 1991-09-12 1993-10-19 Chanel, Inc. Skin cream composition
US5215759A (en) 1991-10-01 1993-06-01 Chanel, Inc. Cosmetic composition
US5217652A (en) 1991-10-04 1993-06-08 The Gillette Company Conditioning shampoo
IT1252061B (it) 1991-11-22 1995-05-29 Gentili Ist Spa Composizioni per uso dermatologico e cosmetico
ATE169826T1 (de) 1992-01-21 1998-09-15 Macrochem Corp Iontophoretische verbesserte verabreichung von medikamenten
JP3302995B2 (ja) 1992-04-01 2002-07-15 株式会社ダイゾー エアゾール組成物
US5632981A (en) 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5691423A (en) 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
US5405919A (en) 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5464954A (en) 1992-08-31 1995-11-07 Idec Izumi Corporation Safety switch assembly
DK169121B1 (da) 1992-09-09 1994-08-22 Gea Farmaceutisk Fabrik As Antiviralt virksom farmaceutisk olie-i-vand-emulsion indeholdende 9-[(2-hydroxyethoxy)methyl]guanin (acyclovir) eller et salt eller en ester deraf
GB9222772D0 (en) 1992-10-30 1992-12-09 Unilever Plc Cosmetic composition
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
JP3191833B2 (ja) 1993-02-24 2001-07-23 三菱東京製薬株式会社 育毛剤
JPH06287135A (ja) 1993-04-01 1994-10-11 Lion Corp 皮膚外用剤組成物
US5439938A (en) 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5852058A (en) 1993-06-11 1998-12-22 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5428070A (en) 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
JP3200723B2 (ja) 1993-08-18 2001-08-20 日本農薬株式会社 育毛剤
DE4338793A1 (de) 1993-11-12 1995-05-18 Froelich Juergen C L-Arginin und Analoge als Thrombozytenaggregationshemmer
DE4341000A1 (de) 1993-12-02 1995-06-08 Beiersdorf Ag Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
GB9409281D0 (en) 1994-05-10 1994-06-29 Svedman Paul Transdermal device
JPH07316075A (ja) 1994-05-26 1995-12-05 Pola Chem Ind Inc 皮膚外用剤
KR100386525B1 (ko) 1994-05-27 2003-08-25 셀레지 파머슈티컬스, 인코포레이티드 산화질소공여체조성물및항문질환의치료방법
US6190704B1 (en) 1994-09-23 2001-02-20 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Regulation of wound healing by nitric oxide
US5543430A (en) 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5505958A (en) 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture
MX9703184A (es) 1994-11-04 1997-12-31 Polymun Scient Inmunbiologisch Aplicacion de superoxido dismutasa en liposomas.
US5594032A (en) 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5648101A (en) 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5853768A (en) 1995-03-01 1998-12-29 Altadonna; James Topical preparation and method for pain relief
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5595753A (en) 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract
US5643586A (en) 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
US5698738A (en) 1995-05-15 1997-12-16 Board Of Regents, The University Of Texas System N-nitroso-N-substituted hydroxylamines as nitric oxide donors
US5762963A (en) 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
US5645859A (en) 1995-10-02 1997-07-08 Isp Investments Inc. Process for producing an alpha or beta-hydroxy acid-vinylpyrrolidone polymer, copolymer or graft polymer complex in the form of free-flowing powders having a high acid loading
US5605685A (en) 1995-09-13 1997-02-25 Isp Investments Inc. Non-irritating skin and hair rejuvenating compostion having a pH between 1 and 6.5
US5734080A (en) 1995-09-22 1998-03-31 Anihealth Corporation Reaction product of arginine and p-aminobenzoic acid, cosmetic, and human and animal health compositions thereof
US6036977A (en) 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
FR2740339B1 (fr) 1995-10-26 1997-12-05 Oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
FR2740453B1 (fr) 1995-10-27 1998-01-16 Bieurope Melanges peptidiques, leur preparation et compositions cosmetiques les contenant
JP2681881B2 (ja) 1995-11-24 1997-11-26 ナショナル サイエンス カウンシル 抗ウイルス剤アシクロビルの経皮吸収製剤
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
JPH09208460A (ja) 1996-01-31 1997-08-12 Lion Corp 貼付剤
JP4020989B2 (ja) 1996-03-06 2007-12-12 株式会社ノエビア 血流促進剤及びこれを配合して成る皮膚外用剤
GB9608408D0 (en) 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
US5911980A (en) 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5891472A (en) 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
JPH10167953A (ja) 1996-12-06 1998-06-23 Daicel Chem Ind Ltd 化粧品組成物
US5807957A (en) 1996-12-23 1998-09-15 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
FR2762782B1 (fr) 1997-05-05 1999-06-11 Oreal Composition comprenant un milieu de culture de micro-organisme et utilisation
WO1999001427A2 (en) 1997-07-03 1999-01-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US5895658A (en) 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
CA2303394C (en) 1997-09-17 2011-12-20 Strategic Science & Technologies, Inc. A delivery of arginine to cause beneficial effects
US7629384B2 (en) 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6207713B1 (en) 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US5922332A (en) 1997-09-17 1999-07-13 Fossel; Eric T. Topical delivery of arginine to overcome pain
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
US5906822A (en) 1997-09-25 1999-05-25 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
JP2002516828A (ja) 1998-06-01 2002-06-11 アンソニー・ジェイ・バービスカー 局所経皮治療
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US6117872A (en) 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
MXPA00012844A (es) 1998-07-07 2004-05-21 Transdermal Technologies Inc Composiciones para la liberacion transdermica rapida y sin irritacion de agentes farmaceuticamente activos y metodos para formular tales composiciones y liberar los mismos.
DE19830649C2 (de) 1998-07-09 2003-04-10 Lohmann Therapie Syst Lts Topisches Pflaster mit nichtsteroidalen Antirheumatika mit Säuregruppe
DE19831798A1 (de) 1998-07-15 2000-01-27 Mandorlo Investment Gmbh Luxem Mittel zur Pflege und/oder Behandlung von Haut und Gewebe
AU1231000A (en) 1998-10-26 2000-05-15 University Of Massachusetts Treatment of skin with adenosine or adenosine analog
US6261594B1 (en) 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
JP2000186028A (ja) 1998-12-21 2000-07-04 Nobuko Koga 化粧品
FR2787996B1 (fr) 1998-12-30 2002-05-10 Dior Christian Parfums Composition cosmetique ou dermatologique contenant un actif stimulant la synthese de la proteine hsp 32 dans la peau et methode de traitement cosmetique
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
JP4538590B2 (ja) 1999-03-12 2010-09-08 エムティ インダストリーズ，インコーポレイテッド 被覆材料を皮膚表面に施すためのミスト装置
US6375672B1 (en) 1999-03-22 2002-04-23 Board Of Trustees Of Michigan State University Method for controlling the chemical and heat induced responses of collagenous materials
FR2794974B1 (fr) 1999-06-16 2001-08-17 Exsymol Sa Composition cosmetique pour l'amincissement a base de l-arginine, d'un analogue de l-arginine ou d'un de leurs derives, applicable par voie topique
WO2001017499A1 (fr) 1999-09-07 2001-03-15 Kabushiki Kaisha Soken Agents d'entretien de la peau
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6602912B2 (en) 2000-06-30 2003-08-05 Dermatrends, Inc. Transdermal administration of phenylpropanolamine
US6565879B1 (en) 1999-12-16 2003-05-20 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
FR2802414B1 (fr) 1999-12-20 2003-06-27 G Pharm Lab Composition, notamment cosmetique ou dermatologique, contenant des oligosaccharides, son procede de preparation et un procede de traitement cosmetique
DE10003767A1 (de) 2000-01-28 2001-10-04 Beiersdorf Ag Hautfreundliches Wirkstoffpflaster zur transdermalen Verabreichung nichtsteroidaler Antirheumatika
JP2001288068A (ja) 2000-04-06 2001-10-16 Nof Corp 皮膚化粧料
FR2810540B1 (fr) 2000-06-21 2004-04-30 C3D Nouvelles preparations cosmetiques ou hygieniques sous forme de dispersion
JP2002003373A (ja) 2000-06-27 2002-01-09 Shiseido Co Ltd 皮膚外用剤
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
HUP0002628A2 (en) 2000-07-14 2002-06-29 Keri Pharma Kft Pharmaceutical combinations for treating diabetes
US6538033B2 (en) 2000-08-29 2003-03-25 Huntington Medical Research Institutes Nitric oxide donor compounds
US6468557B1 (en) 2001-01-05 2002-10-22 Alphamed Pharmaceutical Corp. Method for treating infectious viral diseases
JP2004520388A (ja) 2001-01-25 2004-07-08 ザ ジェネラル ホスピタル コーポレーション しわを治療するためのｎｏｓ阻害剤
WO2002087700A1 (en) 2001-04-26 2002-11-07 The Procter & Gamble Company Method, kit and device for the treatment of cosmetic skin conditions
DE10128910A1 (de) 2001-06-15 2002-12-19 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung
JP4563679B2 (ja) 2001-12-06 2010-10-13 デューク ユニバーシティ 形成外科における組織弁壊死の予防
US20030157185A1 (en) 2002-02-08 2003-08-21 Lou Paradise Topical treatment of neuropathy
WO2003072039A2 (en) 2002-02-22 2003-09-04 Essentia Biosystems, Inc. Cosmetic formulations containing l-arginine oligomers
WO2003078437A1 (en) 2002-03-20 2003-09-25 The University Of Queensland Methods and compositions comprising nitric oxide donors and opioid analgesics
CA2478855C (en) 2002-03-22 2013-12-17 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
JP2003286129A (ja) 2002-03-27 2003-10-07 Hakugen:Kk 痩身シート材
US20030203915A1 (en) 2002-04-05 2003-10-30 Xinqin Fang Nitric oxide donors, compositions and methods of use related applications
RU2229286C2 (ru) 2002-05-27 2004-05-27 Пятигорская государственная фармацевтическая академия Мазь ибупрофена, приготовленная на полиэтиленоксидной основе, обладающая противовоспалительным действием
JP4419368B2 (ja) 2002-07-25 2010-02-24 小野薬品工業株式会社 プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤
US20020168424A1 (en) 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
ATE464043T1 (de) 2002-08-22 2010-04-15 Vasopharm Biotech Gmbh Pharmazeutische zusammensetzung enthaltend l- arginin
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7241456B2 (en) 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
BR0318343A (pt) 2003-05-16 2006-07-11 Lotus Pharmaceutical Co Ltd composição tópica para administração transdérmica
AU2003903037A0 (en) 2003-06-17 2003-07-03 Institute Of Nutraceutical Research Connective tissue derived polypeptides
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US20050069590A1 (en) 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
JP2005200370A (ja) 2004-01-16 2005-07-28 Nikko Chemical Co Ltd 一酸化窒素産生促進剤およびその利用
WO2005081964A2 (en) 2004-02-23 2005-09-09 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US20110028548A1 (en) 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2005102307A2 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
ITMI20041492A1 (it) * 2004-07-23 2004-10-23 Italiano Biochimico Far Maceut Nuovo dispositivo per il rilascio di principi attivi
US20070087977A1 (en) 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
ES2437201T3 (es) 2005-03-03 2014-01-09 Green, Monique Renata Composiciones de geles tópicos
US7442690B2 (en) 2005-03-14 2008-10-28 P & L Enterprise Llc Topical treatment for psoriasis
JP5074401B2 (ja) 2005-09-16 2012-11-14 ガルデルマ・リサーチ・アンド・デヴェロップメント 少なくとも１つのナフトエ酸誘導体および少なくとも１つのポリウレタンポリマータイプの化合物またはその誘導体を含む組成物、その調製方法、およびその使用
EP1770086A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CN101340916A (zh) 2005-12-22 2009-01-07 兴和株式会社 类固醇的经时稳定性得到改善的外用制剂
FR2904549B1 (fr) 2006-08-03 2012-12-14 Sederma Sa Composition comprenant de la sarsasapogenine
AU2007283277A1 (en) 2006-08-11 2008-02-14 The University Of Warwick Osmium compounds
JP5406531B2 (ja) 2006-10-12 2014-02-05 ロート製薬株式会社 皮膚外用剤
WO2008076287A2 (en) 2006-12-13 2008-06-26 Tuel Stephen M Methods of making pharmaceutical components for customized drug products
BRPI0809164B8 (pt) * 2007-03-22 2023-02-28 Berg Llc Composição para administração tópica e composição farmacêutica compreendendo a referida composição
US20080255103A1 (en) 2007-04-12 2008-10-16 Ballay Pharmaceuticals, Inc. Antihistamine and anti-nausea pharmaceutical compositions for topical application
JP2009196934A (ja) 2008-02-21 2009-09-03 Daiichi Sankyo Co Ltd ニューキノロン系抗菌薬及び乳剤性基剤を含む医薬組成物
US8686040B2 (en) 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
US20100099766A1 (en) 2008-10-16 2010-04-22 Novartis Ag Topical NSAID compositions having sensate component
US8969081B2 (en) 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
DK2210588T3 (da) 2008-12-23 2011-06-27 Intendis Gmbh Opskummelig sammensætning, der er i alt væsentligt fri for farmaceutiske aktive indholdsstoffer, til behandling af menneskehud
KR102265757B1 (ko) 2009-03-09 2021-06-17 바이오아트라, 인코퍼레이티드 미락 단백질
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
BRPI1010639A2 (pt) 2009-05-13 2016-03-15 Protein Delivery Solutions Llc sistema farmacêutico para distribuição transmembrana
AU2009348470B2 (en) 2009-06-24 2015-04-02 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
WO2011132826A1 (en) 2010-04-19 2011-10-27 Snu R&Db Foundation Transdermal drug delivery system and pharmaceutical composition for preventing or treating bone diseases
US20120027876A1 (en) * 2010-07-27 2012-02-02 Sara Beth Ford Composition and Method for the Topical Treatment of Dermatitis
WO2012092525A1 (en) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof
WO2012092526A1 (en) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Methods and systems for treatment of migraines and other indications
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
CN103429246A (zh) 2010-12-29 2013-12-04 战略科学与技术有限责任公司 真菌感染和其它适应症的治疗的透皮递送
PT2658551T (pt) 2010-12-29 2020-07-24 Strategic Science & Tech Llc Tratamento da disfunção erétil e outras indicações
WO2012109743A1 (en) 2011-02-18 2012-08-23 Precision Biologic Inc. Methods and compositions relating to coagulation assays
US8833815B2 (en) 2012-10-23 2014-09-16 Ford Global Technologies, Llc Bumper integrated forward radar mounting system
US20160067252A1 (en) 2013-03-15 2016-03-10 Strategic Science & Technologies, Llc Transdermal delivery of sildenafil and other phosphodiesterase type 5 inhibitors
WO2014152280A1 (en) 2013-03-15 2014-09-25 Strategic Science & Technologies, Llc Transdermal formulations of fluticasone
US9819429B2 (en) 2014-10-21 2017-11-14 Qualcomm Innovation Center, Inc. Efficient load sharing and accelerating of audio post-processing
JP2016087702A (ja) 2014-10-29 2016-05-23 日立工機株式会社 電動工具

Also Published As

Publication number Publication date
EP3721893A1 (en) 2020-10-14
US20160263120A1 (en) 2016-09-15
ES2811515T3 (es) 2021-03-12
CN105920603A (zh) 2016-09-07
JP6802879B2 (ja) 2020-12-23
JP2019163307A (ja) 2019-09-26
US9498482B2 (en) 2016-11-22
US9463158B2 (en) 2016-10-11
US20170027942A1 (en) 2017-02-02
US9492458B2 (en) 2016-11-15
CN105920603B (zh) 2022-02-11
US9737543B2 (en) 2017-08-22
US9675619B2 (en) 2017-06-13
HRP20201512T1 (hr) 2020-12-11
US20200237769A1 (en) 2020-07-30
US20170035770A1 (en) 2017-02-09
US20160256381A9 (en) 2016-09-08
EP2658551A1 (en) 2013-11-06
JP2018090599A (ja) 2018-06-14
PT2658551T (pt) 2020-07-24
US20170312288A1 (en) 2017-11-02
JP7187522B2 (ja) 2022-12-12
EP2658551A4 (en) 2015-01-07
JP2021042240A (ja) 2021-03-18
US20160263119A1 (en) 2016-09-15
DK2658551T3 (da) 2020-09-21
JP2014504592A (ja) 2014-02-24
EP2658551B1 (en) 2020-07-01
JP6533840B2 (ja) 2019-06-19
US10682357B2 (en) 2020-06-16
US10898489B2 (en) 2021-01-26
CN103429247A (zh) 2013-12-04
US20140051707A1 (en) 2014-02-20
CN114668851A (zh) 2022-06-28
JP2016135812A (ja) 2016-07-28
WO2012092528A8 (en) 2012-08-09
US20170049778A1 (en) 2017-02-23
JP2022174292A (ja) 2022-11-22
JP7459200B2 (ja) 2024-04-01
US20190083502A1 (en) 2019-03-21
US9833456B2 (en) 2017-12-05
US10172865B2 (en) 2019-01-08
WO2012092528A1 (en) 2012-07-05
US20140086980A1 (en) 2014-03-27
JP6283392B2 (ja) 2018-02-21

Similar Documents

Publication Publication Date Title
EP2658551A4 (en) TREATMENT OF DYSERECTION AND OTHER INDICATIONS
HRP20171352T1 (hr) Wnt-antagonisti i postupci liječenja
IL248530A0 (en) Biomarkers and treatment methods
GB2498121B (en) Treatment device and method of use
EP2709562A4 (en) FABRIC BACKUP DEVICES AND USE METHOD THEREFOR
EP2624790A4 (en) INTERVERTEBRAL DEVICE AND METHODS OF USE
EP2512369A4 (en) GRAFT DEVICES AND METHODS OF USE
EP2654549A4 (en) INTEGRATED SYSTEM ARCHITECTURES AND USE PROCESSES
EP2539005A4 (en) ORAL PIECE AND METHODS OF USING THE SAME
ZA201300612B (en) Novel bacteria and methods of use thereof
EP2536283A4 (en) PHENYLHETEROARYL DERIVATIVES AND USE METHOD THEREFOR
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
EP2608715A4 (en) IMPLANTABLE BIOSENSOR DEVICE AND METHOD FOR THEIR USE
IL265950A (en) Detection and treatment of leprosy
EP2640316A4 (en) FABRIC BACKUP DEVICES AND USE METHOD THEREFOR
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
EP2595695A4 (en) PROCESSING DEVICES AND METHOD FOR THEIR USE
EP2603176A4 (en) C1-C2 IMPLANT AND METHODS OF USE
EP2536709A4 (en) PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE
HK1244706A1 (zh) 用於治療勃起功能障礙的組成物及方法
IL256026A (en) Treatment methods
EP2496597A4 (en) T CELL STIMULATING PROTEIN B AND METHOD FOR ITS USE
EP2640468A4 (en) ADMINISTRATIVE AND TREATMENT PROCEDURES
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法
GB201013698D0 (en) Fixation devices and methods of use thereof